Physician profile

Ernest Eugene Lissy

Family · Stayton, OR

NPI 1013998475

$2,409.27

in general payments reported to CMS, 2019-2025

23 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $348.19 2021-2022
Daiichi Sankyo INC. $320.87 2021-2022
Lilly USA, LLC $283.19 2021-2022
Biohaven Pharmaceuticals, INC. $250.41 2021
Biohaven Pharmaceutical Holding Company LTD. $223.40 2022
Astrazeneca Pharmaceuticals LP $166.46 2021-2022
Sanofi-Aventis U.S. LLC $118.80 2022
Amarin Pharma, INC. $95.42 2021
Janssen Pharmaceuticals, INC $92.79 2021-2022
Pfizer INC. $66.07 2021-2022
Philips North America LLC $61.98 2021
Glaxosmithkline, LLC. $59.16 2021-2022
Otsuka America Pharmaceutical, INC. $53.24 2021-2022
E.R. Squibb & Sons, L.L.C. $51.70 2022
Novo Nordisk INC $41.95 2022
Show all 23 companies
CompanyGeneral paymentsYearsTop products
Merck Sharp & Dohme LLC $33.39 2022
Aspira Women'S Health INC $31.40 2022
Sanofi Pasteur INC. $27.48 2022
Xeris Pharmaceuticals, INC. $22.25 2022
Bayer Healthcare Pharmaceuticals INC. $16.91 2022
Upsher-Smith Laboratories LLC $16.00 2021
Amgen INC. $15.85 2021
Esperion Therapeutics, INC. $12.36 2022

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ernest Eugene Lissy

$2,409.27

in general payments reported 2019-2025

Years
2021-2022
Top company
Abbvie INC.

https://glasscript.com/doctor/11096103/ernest-eugene-lissy

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.